Thursday - October 30, 2025
AstraZeneca: Baxdrostat Met the Primary Endpoint in Bax24 Phase III Trial in Patients With Resistant Hypertension
October 08, 2025
WILMINGTON, Delaware, Oct. 8 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo

*

Positive high-level results from the Bax24 Phase III t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products